Marcus Otho Butler

57PUBLICATIONS
306CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (57)

|Aug 14, 2026
CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles.

|Aug 13, 2026
Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

|Jul 27, 2026
Body Composition and Melanoma Outcomes in Patients on Immunotherapy or Targeted Therapy: An Analysis from Canadian Melanoma Research Network.

|Jan 10, 2026
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Juan Alban, R Christopher Bowen, David A Reichstein

|Jan 03, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

April A N Rose, Jennifer Maxwell, Emmanuelle Rousselle

|Nov 11, 2025
Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation.

Vincent Rondeau, Suraj Bansal, Marco M Buttigieg

Pageof 10

Frequent Collaborators

9 joint publications

Naoto Hirano

8 joint publications

Paolo A Ascierto

6 joint publications

Anna Spreafico

5 joint publications

Jean-Jacques Grob